|
|
|
17.03.26 - 08:03
|
Samsung Ventures Joins GridBeyond′s Shareholder Base as Part of a €12M Equity Investment (Business Wire)
|
|
|
NEW YORK--(BUSINESS WIRE)--Samsung Ventures (Samsung) has invested in GridBeyond as part of a €12M equity round alongside existing shareholders including Alantra's Energy Transition Fund, Klima, Energy Impact Partners, Mirova, ABB, Constellation Technology Ventures, and Act Venture Capital. Together with longstanding existing shareholders, Yokogawa, EDP & Enterprise Ireland they continue to support the company's growth.
GridBeyond, a global leader in intelligent energy technology and optimisation of distributed energy assets will work closely with Samsung to explore opportunities across trading, asset optimisation and energy services that will allow both companies to realise their growth ambitions globally.
The funding will accelerate the expansion across GridBeyond's key strategic markets including the UK, Ireland, the United States, Japan, and Australia, while enabling continued investment in the evolution of the company's optimisation platform for distributed energy assets.
GridBeyond's technolo...
|
|
|
13.03.26 - 12:03
|
Statkraft joins leading power companies in call to safeguard EU ETS and strengthen Europe′s competitiveness (GlobeNewswire EN)
|
|
|
(Oslo / Brussels, 13 March 2026) Eight major European energy companies urge EU leaders to protect proven market mechanisms and accelerate the clean energy transition.– Statkraft, Europe's largest renewable energy producer, joins seven other major European power companies in a joint call to EU leaders, urging them to reinforce Europe's competitiveness by safeguarding the EU Emissions Trading System (EU ETS), preserving the internal electricity market and marginal pricing, and accelerating decarbonisation.In a letter addressed to European Commission President Ursula von der Leyen and European Council President António Costa, Statkraft, Fortum, Vattenfall, Iberdrola, EDP, Ørsted, EDF and Engie warn against dismantling well‑functioning market mechanisms that underpin investment, security of supply and affordable energy across Europe. “Weakening the EU ETS will not solve Europe's competitiveness challenges. On the contrary, it can lead to increased uncertainty and slow down the power sector investm...
|
|
|
|
|
04.03.26 - 12:12
|
EDP, EDP Renováveis Shares Edge Up (AFX)
|
|
|
MADRID (dpa-AFX) - Portuguese electric utility company EDP Group's shares were gaining around 0.6 percent in Lisbon on Wednesday, and shares of its Spanish renewable energy subsidiary EDP Renováve......
|
|
|
04.03.26 - 12:02
|
EDP CEO: Energy Shock From War Fueling Clean Power Demand (Bloomberg)
|
|
|
Portuguese utility EDP CEO Miguel Stilwell de Andrade joins Bloomberg TV to discuss how the war in the Middle East is boosting demand for renewables, as countries and businesses seek to diversify their sources of energy and shield themselves from external shocks.
Stilwell de Andrade speaks with Bloomberg's Lizzy Burden, Tom Mackenzie and Anna Edwards on The Opening Trade. (Source: Bloomberg)...
|
|
|
|
|
|
|
|
|
10.02.26 - 13:03
|
Enanta Pharmaceuticals to Present Preclinical Data for EDP-978, its KIT Inhibitor in Development for the Treatment of Type 2 Immune Diseases, at the 2026 AAAAI Annual Meeting (Business Wire)
|
|
|
WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological diseases today announced that preclinical data for EDP-978, the Company's KIT inhibitor in development for the treatment of mast cell-mediated, Type 2 immune diseases, will be presented in two poster presentations at the 2026 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting being held February 27 – March 2, 2026 in Philadelphia, PA.
Details of the presentations are as follows:
Abstract Title: Discovery of a Potent and Selective KIT inhibitor for Treatment of Mast Cell-Mediated Diseases
Date: Friday, February 27, 2026
Time: 2:45 – 3:45 PM EST
Poster Number: 104
Session: Allergic Skin Diseases
Location: Convention Center, Level 2, Hall E
Presenter: Tessa Cressey, Ph.D.
Abstract Title: EDP-978, a Potent KIT Inhibitor, Demonstrated Dose-Dependent Target-Engagement and a Favorable Pharm...
|
|
|
09.02.26 - 22:03
|
Enanta Pharmaceuticals Reports Financial Results for its Fiscal First Quarter Ended December 31, 2025 (Business Wire)
|
|
|
Conducting Phase 3 Enabling Activities, Including Discussions with U.S. Food & Drug Administration (FDA), for Zelicapavir, an N-Protein Inhibitor in Development to Treat Respiratory Syncytial Virus (RSV)
Introduced New Immunology Program Focused on MRGPRX2 Inhibition; On Track to Select a Development Candidate in 2H 2026
On Track to File an Investigational New Drug Application (IND) in 1Q 2026 and Report Phase 1 Data in 4Q 2026 for EDP-978, an Oral, Once-Daily KIT Inhibitor Clinical Candidate
On Track to File an IND in 2H 2026 for EPS-3903, an Oral, Once-Daily STAT6 Inhibitor Development Candidate
Strong Financial Position of $241.9 Million Supported by Continuing Retained Royalties, with Cash Runway Expected to Fund Operations into Fiscal 2029
WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological diseases, today reported financial results for its fiscal first q...
|
|
|
|
|
|
|
17.11.25 - 22:06
|
Enanta Pharmaceuticals Reports Financial Results for its Fiscal Fourth Quarter and Year-Ended September 30, 2025 (Business Wire)
|
|
|
Announces EPS-3903, an Oral, Once-Daily STAT6 Inhibitor Development Candidate with Rapid, Continuous and Complete (>90%) In Vivo pSTAT6 Suppression and Efficacy Comparable to Dupilumab in Asthma and Atopic Dermatitis Disease Models
Announces EDP-978, an Oral, Once-Daily KIT Inhibitor Clinical Candidate with Plans to File an Investigational New Drug Application in Q1 2026
Reported Positive Topline Data for RSVHR, a Phase 2b Study of Zelicapavir in High-Risk Adults Infected with Respiratory Syncytial Virus (RSV)
Strong Financial Position Ending Fiscal 2025 with $188.9 Million in Cash, Cash Equivalents and Marketable Securities; Further Strengthened by Gross Proceeds of $74.8 Million Upsized Public Offering in October 2025 and Continuing Retained Royalties, Expected to Fund Operations into Fiscal 2029
WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological diseases, ...
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
